INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 187 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,459 | -52.6% | 3,750 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $3,075 | 0.0% | 3,750 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $3,075 | -47.4% | 3,750 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $5,850 | -2.5% | 3,750 | 0.0% | 0.00% | -20.0% |
| Q3 2022 | $6,000 | 0.0% | 3,750 | 0.0% | 0.01% | +25.0% |
| Q2 2022 | $6,000 | -53.8% | 3,750 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $13,000 | -31.6% | 3,750 | 0.0% | 0.01% | -27.3% |
| Q4 2021 | $19,000 | -29.6% | 3,750 | 0.0% | 0.01% | -38.9% |
| Q3 2021 | $27,000 | -22.9% | 3,750 | 0.0% | 0.02% | -25.0% |
| Q2 2021 | $35,000 | 0.0% | 3,750 | 0.0% | 0.02% | -7.7% |
| Q1 2021 | $35,000 | +6.1% | 3,750 | 0.0% | 0.03% | -3.7% |
| Q4 2020 | $33,000 | -25.0% | 3,750 | 0.0% | 0.03% | -35.7% |
| Q3 2020 | $44,000 | -56.4% | 3,750 | 0.0% | 0.04% | -60.4% |
| Q2 2020 | $101,000 | +260.7% | 3,750 | 0.0% | 0.11% | +211.8% |
| Q1 2020 | $28,000 | +7.7% | 3,750 | -51.6% | 0.03% | +36.0% |
| Q4 2019 | $26,000 | – | 7,750 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |